EcoDrugPlus

Receptor Activity Modifying Protein 1

Ensembl ID : ENSSTUG00000040097
Gene Symbol: RAMP1
3 Cross references
178 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSSTUG00000026911
Gene Symbol: RAMP1
1 Cross references
178 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSSTUG00000009887
Gene Symbol: LOC115155558
3 Cross references
183 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSSTUG00000010313
Gene Symbol: LOC115160877
3 Cross references
186 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSSTUG00000050555
Gene Symbol: RIPK1
3 Cross references
191 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSSTUG00000027406
Gene Symbol: LOC115165511
3 Cross references
199 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSSTUG00000047215
Gene Symbol: LOC115167852
3 Cross references
199 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4-Like

Ensembl ID : ENSSTUG00000040105
Gene Symbol: LOC115179194
2 Cross references
225 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4-Like

Ensembl ID : ENSSTUG00000026883
Gene Symbol: LOC115196465
2 Cross references
228 Possible Orthologues:

Receptor-Interacting Serine/threonine-Protein Kinase 1-Like

Ensembl ID : ENSSTUG00000016994
Gene Symbol: LOC115169632
3 Cross references
192 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSSTUG00000021142
Gene Symbol: RPTOR
3 Cross references
205 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSSTUG00000043832
Gene Symbol: RPTOR
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).